Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan Jarow

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Clinical Trials (London, England)|March 28, 2017
Sponsors' and investigative staffs' perceptions of the current investigational new drug safety reporting process in oncology trialsRaymond Perez, Patrick Archdeacon, Nancy Roach, et al.
Bladder Cancer (Amsterdam, Netherlands)|April 19, 2016
Development of Systemic and Topical Drugs to Treat Non-muscle Invasive Bladder CancerJonathan Jarow, V Ellen Maher, Shenghui Tang, et al.
Journal of Andrology|October 22, 2011
Simultaneous quantification of steroids in rat intratesticular fluid by HPLC-isotope dilution tandem mass spectrometryAlissa Renne, Lindi Luo, Jonathan Jarow, et al.
European Urology|October 20, 2007
An evaluation of semen characteristics in men 45 years of age or older after daily dosing with tadalafil 20mg: results of a multicenter, randomized, double-blind, placebo-controlled, 9-month studyWayne J G Hellstrom, Marc Gittelman, Jonathan Jarow, et al.
The Journal of Urology|September 23, 2003
American Urological Association guideline on the management of priapismDrogo K Montague, Jonathan Jarow, Gregory A Broderick, et al.
The Journal of Urology|June 18, 2004
AUA guideline on the pharmacologic management of premature ejaculationDrogo K Montague, Jonathan Jarow, Gregory A Broderick, et al.
Urology|July 29, 2014
Reply by the authorsJonathan Jarow, Paul G Kluetz, Seth P Lerner, et al.
Clinical Pharmacology and Therapeutics|February 24, 2018
Considerations for Developing Targeted Therapies in Low-Frequency Molecular Subsets of a DiseaseRobert N Schuck, Janet Woodcock, Issam Zineh, et al.
The Journal of Urology|September 11, 2019
Development of Treatments for Localized Prostate Cancer in Patients Eligible for Active Surveillance: U.S. Food and Drug Administration Oncology Center of Excellence Public WorkshopChana Weinstock, Daniel Suzman, Paul Kluetz, et al.
Bladder Cancer (Amsterdam, Netherlands)|July 5, 2016
Summary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder CancerSeth P Lerner, Dean F Bajorin, Colin P Dinney, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Clinical Trials (London, England)|March 28, 2017
Sponsors' and investigative staffs' perceptions of the current investigational new drug safety reporting process in oncology trialsRaymond Perez, Patrick Archdeacon, Nancy Roach, et al.
Bladder Cancer (Amsterdam, Netherlands)|April 19, 2016
Development of Systemic and Topical Drugs to Treat Non-muscle Invasive Bladder CancerJonathan Jarow, V Ellen Maher, Shenghui Tang, et al.
Journal of Andrology|October 22, 2011
Simultaneous quantification of steroids in rat intratesticular fluid by HPLC-isotope dilution tandem mass spectrometryAlissa Renne, Lindi Luo, Jonathan Jarow, et al.
European Urology|October 20, 2007
An evaluation of semen characteristics in men 45 years of age or older after daily dosing with tadalafil 20mg: results of a multicenter, randomized, double-blind, placebo-controlled, 9-month studyWayne J G Hellstrom, Marc Gittelman, Jonathan Jarow, et al.
The Journal of Urology|September 23, 2003
American Urological Association guideline on the management of priapismDrogo K Montague, Jonathan Jarow, Gregory A Broderick, et al.
The Journal of Urology|June 18, 2004
AUA guideline on the pharmacologic management of premature ejaculationDrogo K Montague, Jonathan Jarow, Gregory A Broderick, et al.
Urology|July 29, 2014
Reply by the authorsJonathan Jarow, Paul G Kluetz, Seth P Lerner, et al.
Clinical Pharmacology and Therapeutics|February 24, 2018
Considerations for Developing Targeted Therapies in Low-Frequency Molecular Subsets of a DiseaseRobert N Schuck, Janet Woodcock, Issam Zineh, et al.
The Journal of Urology|September 11, 2019
Development of Treatments for Localized Prostate Cancer in Patients Eligible for Active Surveillance: U.S. Food and Drug Administration Oncology Center of Excellence Public WorkshopChana Weinstock, Daniel Suzman, Paul Kluetz, et al.
Bladder Cancer (Amsterdam, Netherlands)|July 5, 2016
Summary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder CancerSeth P Lerner, Dean F Bajorin, Colin P Dinney, et al.
Pageof 1